Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer granted approval for reformulated liquid Leukine
The new formulation does not contain EDTA (edetate disodium), which was in the product’s liquid 500 mcg vial manufactured from January 2006 to January 2008. With the approval
The new formulation does not contain EDTA (edetate disodium), which was in the product’s liquid 500 mcg vial manufactured from January 2006 to January 2008. With the approval
Prostate Px+ is based on the results of a large study utilizing data and samples from a cohort of 1,027 men assembled from the Mayo Clinic, Uppsala University,
In the multi-center, randomized, double-blind, placebo-controlled Phase II study mechanically ventilated patients (MVP) received 400 mg doses of amikacin with Amikacin Inhale every 24 hours (n=24) or every
H19 genes are expressed post-natally only in cancerous cells and are believed to enable tumor cells to survive and proliferate. Small interfering Ribonucleic Acid (siRNA) are a class
RainDance said it will open the new facility and start up commercial and manufacturing operations, effective May 27, 2008. The company also said that it will employ approximately
The series A financing is being co-led by founding investors Atlas Venture and Boulder Ventures, and includes additional investments from private individuals. The funding will be employed to
VGX-3100 is a DNA-based therapeutic vaccine that has the potential to treat cervical cancer caused by the human papilloma virus (HPV). VGX-3100 utilizes synthetic consensus sequences based on
Lakewood’s national gastrointestinal (GI) services were developed using Next Level Diagnostics, which are enhanced procedures and processes inserted throughout the testing process to ensure the highest level of
The study was a Phase I, randomized, single blind, placebo-controlled, single center dose escalation study of a single bolus injection of IK-1001 (sodium sulfide) in healthy volunteers to
PerkinElmer’s current CFO, Jeffrey Capello, is resigning to pursue another opportunity outside the company, effective June 6, 2008. Since Mr Battles joined PerkinElmer in 2001 as controller for